Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Wave Life Sciences (WVE) over the last 11 years, with Sep 2025 value amounting to -$248,000.

  • Wave Life Sciences' Cash from Investing Activities rose 35.25% to -$248,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$805,000, marking a year-over-year increase of 33.36%. This contributed to the annual value of -$938,000 for FY2024, which is 15.87% up from last year.
  • Per Wave Life Sciences' latest filing, its Cash from Investing Activities stood at -$248,000 for Q3 2025, which was up 18.95% from -$306,000 recorded in Q2 2025.
  • Over the past 5 years, Wave Life Sciences' Cash from Investing Activities peaked at $24.8 million during Q4 2022, and registered a low of -$50.2 million during Q1 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$248,000 (2025), whereas its average is -$252,000.
  • Over the last 5 years, Wave Life Sciences' Cash from Investing Activities had its largest YoY gain of 165,700.00% in 2022, and its largest YoY loss of 46,388.89% in 2022.
  • Over the past 5 years, Wave Life Sciences' Cash from Investing Activities (Quarterly) stood at -$15,000 in 2021, then skyrocketed by 165,700.00% to $24.8 million in 2022, then plummeted by 101.43% to -$356,000 in 2023, then skyrocketed by 75.84% to -$86,000 in 2024, then spiked by 35.25% to -$248,000 in 2025.
  • Its last three reported values are -$248,000 in Q3 2025, -$306,000 for Q2 2025, and -$165,000 during Q1 2025.